Select Page ::

Neurological charity’s donations to be doubled with match-funding next month – In Your Area

Posted on November 30, 2020 by Danzig

InYourArea Community

Between December 1 and December 8, there'll 10,000 of match-funding available for donations to Neuro Therapy Centres

Centre member Clare Moulton using the Neuro Therapy Centres gym

Submitted by The Neuro Therapy Centre, edited by Lucy Hilton

A local charity is calling for community support as they're given a fantastic opportunity.

The team at the Neuro Therapy Centre have recently made their 5,000th support call, as their services support people with neurological conditions across the region.

They're now asking for help to keep their Virtual Centre going as donations supporting their services will be match-funded next month.

Staff at the Centre are urging as many people to get involved as possible at this important time by making a donation to help fund their vital work.

The Centre started offering many of its life-changing services online in April as a result of the pandemic, and as they adapted their delivery, the charity has found new ways to help people across the region with plans to expand their work in the future.

Jane Johnston-Cree, Centre Director at the Neuro Therapy Centre said: "This year has been a challenging one for all of us.

The Centres virtual services now feature regular telephone support, telephone and online counselling sessions, nine live exercises sessions a week and a range of recorded exercise sessions and therapies.

Jane added: "Our virtual services are helping people who sometimes find it a struggle to visit our Centre in Saltney due to transport or work commitments.

Clare Moulton, from Sychdyn in Flintshire, was diagnosed with MS in 1997, and has been attending physiotherapy and gym sessions at the Neuro Therapy Centre since 2018.

The Centre re-opened in September for in-Centre services but it will be next year before the same number of people will be able to attend its services on a weekly basis in person.

Jane said: "We intend to keep our virtual centre going alongside our in-Centre services in the future, which is why wed love as many people as possible to get behind our match-funding Big Give campaign.

"We know transport can be a real issue, and if these services can help people who have been newly diagnosed and are still in work too that would be fantastic."

Between noon on December 1 and noon on December 8, the Neuro Therapy Centres Big Give web page will be live, and there is 10,000 of match-funding available for donations of any size to be doubled for free.

The Centre also has an online Christmas Concert with local artists Matt Violet and The Last Minute performing on Saturday, December 5, and is encouraging people to wear a Christmas jumper and make a donation to the site during that week.

If people would like to make a donation to the Neuro Therapy Centre visit their Big Give page.

The Neuro Therapy Centre, based in Saltney, Chester, supports people with neurological conditions including MS, Parkinsons, ME and MND, and their Carers from across Cheshire, North Wales and the Wirral.

If people would like to find out more about the services of the Neuro Therapy Centre or to book a ticket for the Christmas Concert visit their website.

Shine a spotlight on your neighbourhood by becoming an Area Ambassador.

Click here to learn more!

Continued here:
Neurological charity's donations to be doubled with match-funding next month - In Your Area

Brain Monitoring Devices Market: High incidence of neurological disorders to drive the market – BioSpace

Posted on November 13, 2020 by Danzig

Global Brain Monitoring Devices Market: Overview

The National Institute of Mental Health in the US states that every 1 in 4 adults suffers from a brain disorder every year. It further asserts that at least 6% suffer from serious disabilities due to severe brain damage. This alarming statistic goes to show the dire need for brain monitoring devices in the global healthcare industry today. Research shows that brain monitoring devices will be in significant demand in critical care units due to a high incidence of accidents pertaining to brain trauma and injuries in recent past. The market offers a wide range of devices to treat the abnormal brain activities and restore its functioning, depending on the case.

The global brain monitoring market has been analyzed by researchers at Transparency Market Research using foolproof research methodologies. The document has been collaborated using information from various journals, interviews, whitepapers, conferences, and magazines. The report also includes an assessment of the competitive landscape present in the global brain monitoring devices market. It offers a thorough understanding of the overall market dynamics and maps a plausible trajectory for the market.

Request Brochure of Report - https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=1322

Global Brain Monitoring Devices Market: Drivers and Trends

The high incidence of neurological disorders in recent years due to changing lifestyles, rising stress levels, and radical changes in the social environments have cumulatively augmented the demand for brain monitoring devices market. Today, these devices are used for understanding the conditions of patients suffering from Alzheimers disease, epilepsy, multiple sclerosis, and brain tumors amongst others. Thus, the increasing number of patients suffering from these conditions are expected to serve as a strong market driver for the global brain monitoring devices market.

The various brain monitoring devices available in the global market are intracranial pressure monitors, magnetoencephalography, electroencephalograph, cerebral oximeters, and transcranial doppler. These devices track brain function such as the velocity of blood flow in the veins and arteries in case of epilepsy, pressure surrounding the brain, electrical and neural activity, brain death, and traumatic brain injury. The market is also growing due to the rising number of post-surgical cerebrovascular accidents. These incidences have led to an augmented demand for automated brain monitoring devices in clinics and hospitals to understand the impact of anesthesia and sedatives.

Analysts note that the improvement in functionality of these devices, their user-friendliness, and affordability along with technological advancements will encourage the growth of the global market in the coming years.

Request for Analysis of COVID-19 Impact on Brain Monitoring Devices Market - https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=1322

Global Brain Monitoring Devices Market: Geographical Outlook

On the basis of region, the global brain monitoring devices market is segmented into Asia Pacific, North America, Europe, and Rest of the World. Analysts predict that North America is expected to lead the global market as the region has a strong healthcare infrastructure. The high adoption of technology and high penetration of mobile device have given this market an edge over other regions. The brain monitoring devices market in North America is also being encouraged by the supportive regulatory framework and affordable healthcare plans. The significant rise in the geriatric population has also made its contribution to the rise of the brain monitoring devices market in North America. Research indicates that rising patient awareness about benefits of brain monitoring devices to treat disorders such as sleep apnea, Alzheimers disease, and epilepsy amongst others will also propel the regional market.

Request for Custom Research - https://www.transparencymarketresearch.com/sample/sample.php?flag=CR&rep_id=1322

Key Players Mentioned in the Report

Some of the leading players operating in the global brain monitoring devices market are Advanced Brain Monitoring, Inc., Covidien PLC, Natus Medical, Inc., and Nihon Kohden Corporation.

This study by TMR is all-encompassing framework of the dynamics of the market. It mainly comprises critical assessment of consumers' or customers' journeys, current and emerging avenues, and strategic framework to enable CXOs take effective decisions.

Pre Book Brain Monitoring Devices Market Report at https://www.transparencymarketresearch.com/checkout.php?rep_id=1322&ltype=S

Our key underpinning is the 4-Quadrant Framework EIRS that offers detailed visualization of four elements:

The study strives to evaluate the current and future growth prospects, untapped avenues, factors shaping their revenue potential, and demand and consumption patterns in the global market by breaking it into region-wise assessment.

Neurovascular Devices/Interventional Neurology Market Forecast to 2028: How it is Going to Impact on Global Industry to Grow in Near Future -…

Posted on November 20, 2020 by Danzig

Neurovascular Devices/Interventional Neurology Market 2020: Latest Analysis:

The most recent Neurovascular Devices/Interventional Neurology Market Research study includes some significant activities of the current market size for the worldwide Neurovascular Devices/Interventional Neurology market. It presents a point by point analysis dependent on the exhaustive research of the market elements like market size, development situation, potential opportunities, and operation landscape and trend analysis. This report centers around the Neurovascular Devices/Interventional Neurology-business status, presents volume and worth, key market, product type, consumers, regions, and key players.

Sample Copy of This Report @ https://www.quincemarketinsights.com/request-sample-59263?utm_source=Technoweekly/komal

The prominent players covered in this report: Stryker Corporation , Medtronic plc, Johnson & Johnson, Terumo Corporation, Penumbra, Inc., Abbott Laboratories, Merit Medical Systems, Inc., W. L. Gore & Associates, Inc., MicroPort Scientific Corporation.

The market is segmented into By Product (Embolic Coils, Stents, Neurothrombectomy Devices, Microcatheters, Balloon Occlusion Devices, Flow Diversion Devices, Clot Retrievers),By Pathology (Aneurysm, AVM).

Geographical segments are North America, Europe, Asia Pacific, Middle East & Africa, and South America.

It has a wide-ranging analysis of the impact of these advancements on the markets future growth, wide-ranging analysis of these extensions on the markets future growth. The research report studies the market in a detailed manner by explaining the key facets of the market that are foreseeable to have a countable stimulus on its developing extrapolations over the forecast period.

Get ToC for the overview of the premium report @ https://www.quincemarketinsights.com/request-toc-59263?utm_source=Technoweekly/komal

This is anticipated to drive the Global Neurovascular Devices/Interventional Neurology Market over the forecast period. This research report covers the market landscape and its progress prospects in the near future. After studying key companies, the report focuses on the new entrants contributing to the growth of the market. Most companies in the Global Neurovascular Devices/Interventional Neurology Market are currently adopting new technological trends in the market.

Finally, the researchers throw light on different ways to discover the strengths, weaknesses, opportunities, and threats affecting the growth of the Global Neurovascular Devices/Interventional Neurology Market. The feasibility of the new report is also measured in this research report.

Reasons for buying this report:

Make an Enquiry for purchasing this Report @ https://www.quincemarketinsights.com/enquiry-before-buying/enquiry-before-buying-59263?utm_source=Technoweekly/komal

About Us:

QMI has the most comprehensive collection of market research products and services available on the web. We deliver reports from virtually all major publications and refresh our list regularly to provide you with immediate online access to the worlds most extensive and up-to-date archive of professional insights into global markets, companies, goods, and patterns.

Quince Market Insights

Ajay D. (Knowledge Partner)

Office No- A109

Pune, Maharashtra 411028

Phone: APAC +91 706 672 4848 / US +1 208 405 2835 / UK +44 1444 39 0986

Email: [emailprotected]

Web: https://www.quincemarketinsights.com

Here is the original post:
Neurovascular Devices/Interventional Neurology Market Forecast to 2028: How it is Going to Impact on Global Industry to Grow in Near Future -...

NeurOptics’ Neurological Pupil index and Automated Pupillometry Included in New American Heart Association Guidelines for CPR and Emergency…

Posted on November 20, 2020 by Danzig

LAGUNA HILLS, Calif.--(BUSINESS WIRE)--NeurOptics Neurological Pupil index (NPi) and automated pupillometry are now included in the updated 2020 American Heart Association (AHA) Guidelines for Cardiopulmonary Resuscitation (CPR) and Emergency Cardiovascular Care (ECC) as an objective measurement supporting brain injury prognosis in patients following cardiac arrest.

The AHA guidelines outline the latest global resuscitation science and treatment recommendations derived from the 2020 International Consensus on CPR and ECC and are considered the gold standard of clinical recommendations in the practice of resuscitation science. The guidelines were last updated in 2015 and reflect alignment with the International Liaison Committee on Resuscitation and associated member councils.

Automated infrared pupillometry is an objective assessment of the pupillary light reflex that is measured using NeurOptics NPi-200 Pupillometer. The NPi-200 Pupillometer provides an objective measurement of pupil size and reactivity and calculates the Neurological Pupil index (NPi). NPi values range from 0 to 4.9, with scores under 3 considered abnormal. The NeurOptics NPi-200 Pupillometer eliminates the variability and subjectivity inherent in manual pupillary evaluation, providing more accurate, reliable, and objective pupil size and reactivity measurement for this vital component of neurological examinations in patients with the potential for brain injury across a broad spectrum of conditions, including patients who have suffered cardiac arrest.

According to the new AHA guidelines, most deaths attributable to post-cardiac arrest brain injury are due to active withdrawal of life-sustaining treatment based on a predicted poor neurological outcome.1 Automated assessment of pupillary reactivity, measured by the NPi, provides a standard, reproducible measurement of pupil size and reactivity to help support the prognosis of poor neurological outcome in patients who remain comatose 72 hours after cardiac arrest.1-3

The expansion of the AHA guidelines to include automated pupillometry with the Neurological Pupil index (NPi) to monitor patients who have suffered a cardiac arrest reflects the growing adoption and validation of automated pupillometry for use in patients with brain injury, said William Worthen, President and CEO of NeurOptics. The NPi scale removes subjectivity from the neurological evaluation, providing clinicians with more accurate, objective and reliable pupil data that can be trended over time, and allows earlier detection of changes for timelier patient treatment. We are pleased to see automated pupillometry included in these new guidelines.

The 2020 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care were published in the journal Circulation, and can be found here.

About NeurOptics

Headquartered in Laguna Hills, Calif., NeurOptics is the leader in the science of pupillometry. Driven by a passion to help clinicians improve patient outcomes, NeurOptics develops and markets innovative technology for use in critical care medicine, neurology, neurosurgery, emergency medicine, and research. The NeurOptics NPi-200 Pupillometer has been included in more than 50 clinical studies, adopted in over 440 trauma and stroke centers in the United States, and is represented in more than 26 countries worldwide. For more information, visit http://www.NeurOptics.com. Follow NeurOptics on Facebook, LinkedIn and Twitter @NeurOpticsInc.

References

Go here to read the rest:
NeurOptics' Neurological Pupil index and Automated Pupillometry Included in New American Heart Association Guidelines for CPR and Emergency...

CODA Biotherapeutics Receives Grant from the National Institute of Neurological Disorders and Stroke (NINDS) of the National Institutes of Health…

Posted on November 13, 2020 by Danzig

SOUTH SAN FRANCISCO, Calif., Nov. 10, 2020 /PRNewswire/ -- CODA Biotherapeutics, Inc., a preclinical-stage biopharmaceutical company developing a gene therapy-mediated chemogenetic platform to treat neurological disorders and diseases with an initial focus on neuropathic pain and epilepsy, today announced it has been awarded a Small Business Innovation Research (SBIR) grant from the National Institute of Neurological Disorders and Stroke (NINDS) of the National Institutes of Health (NIH). As part of theNIH Helping to End Addiction Long-term InitiativeSM, or NIH HEAL InitiativeSM, the funding of $670,000 over two years will be used to support CODA's plans to evaluate and advance the Company's unique receptor-ligand pairs toward the clinic for the treatment of neuropathic pain. Orion P. Keifer, Jr. M.D., Ph.D., Vice President, Discovery and Translation at CODA, will serve as the program's principal investigator.

"We are unwavering in our commitment to developing novel chemogenetic therapies for the treatment of neurological disorders and diseases like neuropathic pain for which current treatment options have significant limitations," said Michael Narachi, President and Chief Executive Officer, CODA. "We are honored to receive this grant from NINDS, as this funding will help advance our chemogenetic platform toward human clinical trials where we hope to demonstrate transformative results for patients."

CODA Biotherapeutics is developing a paradigm-shifting gene therapy approach for neuropathic pain by deploying a chemogenetic strategy for treating neuropathic pain sensations at their origin. The Company's innovative treatment aims to modulate specific neuronal circuits where pain arises via adeno-associated virus-mediated delivery of an engineered inhibitory receptor. The receptor is designed to be quiescent in the transduced cells but will specifically and dose-dependently inhibit neurons when exposed to a novel, orally bioavailable small-molecule agonist. CODA expects this treatment will produce substantially improved and durable pain relief while potentially avoiding off-target/adverse effects of currently available treatments.

The NINDS SBIR/Small Business Technology Transfer (STTR) program funds small business concerns to conduct innovative neuroscience research and/or development that has both the potential for commercialization and public health benefit.

In addition, CODA was recently selected to collaborate with NIH's National Center for Advancing Translational Science (NCATS), also as part of the NIH HEAL initiative. CODA will partner with the Stem Cell Translation Laboratory led by Ilyas Singec, M.D., Ph.D., in the NCATS Division of Preclinical Innovation (DPI) in developing induced pluripotent stem cell (iPSC)-derived human Ab sensory neurons for the identification and characterization of novel neuropathic pain therapies. The joint NCATS/CODA collaboration will leverage expertise and technologies available at Dr. Singec's lab to jointly develop protocols for generating iPSC-derived A primary sensory neurons, which CODA will then use for the identification and evaluation of inhibitory chemogenetic receptors for the treatment of neuropathic pain. G. Steven Dodson, Ph.D., Vice President of Pharmacology and Early Development at CODA will serve as lead collaborator.

"Ab neurons are a key cell type for the evaluation of our receptor-ligand combinations and their development should advance the translational understanding of how our approach may impact pain states in patients. Through this partnership, CODA will collaborate with and gain access to the scientific capabilities, expertise, state-of-the-art technologies, and resources of the NCATS DPI to develop iPSC-derived human Ab sensory neurons, which will help us progress our neuropathic pain therapies toward the clinic," added Mr. Narachi.

About Neuropathic Pain According to a study published in the Journal of Pain Research, 10 percent of the U.S. population suffers from neuropathic pain an estimated 30 million Americans. Neuropathic pain is caused by damage or disease of the sensory system, leading to chronic debilitation and loss of quality of life. Current pharmacological therapies for chronic neuropathic pain, such as opioids, anticonvulsants, and tricyclic anti-depressants, are not always effective and can have side effects, including the potential for addiction.

About the CODA Platform CODA's chemogenetic platform aims to reverse the aberrant neuronal activity underlying many neurological disorders. With chemogenetics, dysfunctional neurons are modified using optimized adeno-associated virus (AAV) vectors delivered directly to them by standard-of-care neurosurgical procedures. The AAV vectors encode ligand-gated ion channels (chemogenetic receptors) that are highly responsive to specific proprietary small molecule therapeutics but are otherwise inactive. The activity of these receptors, and thus the aberrant activity of the modified neurons, is controlled in a selective and tunable manner through administration of the small molecule to generate therapeutic benefit with minimal side effects.

About CODA BiotherapeuticsCODA Biotherapeutics, Inc., is a preclinical-stage biopharmaceutical company developing an innovative gene therapy platform to treat neurological disorders and diseases. The Company is creating the ability to control neurons with its revolutionary chemogenetics-based technology. CODA is located in South San Francisco, CA. For more information, please visit http://www.codabiotherapeutics.com.

View original content to download multimedia:http://www.prnewswire.com/news-releases/coda-biotherapeutics-receives-grant-from-the-national-institute-of-neurological-disorders-and-stroke-ninds-of-the-national-institutes-of-health-nih-to-help-advance-its-next-generation-gene-therapy-mediated-chemogenetic-platfor-301168028.html

SOURCE CODA Biotherapeutics, Inc.

See the rest here:
CODA Biotherapeutics Receives Grant from the National Institute of Neurological Disorders and Stroke (NINDS) of the National Institutes of Health...

Global Interventional Neurology Device Market 2020 | Demand and Scope with Outlook, Business Strategies, Challenges and Forecasts to 2025 -…

Posted on November 13, 2020 by Danzig

MarketsandResearch.biz has published a new report titled Global Interventional Neurology Device Market 2020 by Manufacturers, Type and Application, Forecast to 2025 that aims to define the market size of different segments in previous years and to forecast the values to the next five years. The report entails a comprehensive database on market estimation based on historical data analysis. The report emphasizes knowledge-based information on both qualify qualitative and quantitative aspects of the industry. It covers the new players entering the global Interventional Neurology Device market. It focuses on primary and secondary drivers, market share, leading segments, and regional analysis. Then the report demonstrates detailed information about the crucial aspects such as drivers and restraining factors which will show the future growth of the market.

The most recent improvements and new industrial explanations are revealed in the report. Report analysts analyze the key elements such as demand, growth rate, cost, capacity utilization, import, margin, and production of the global market players. The report further focuses on global major leading industry players of the global Interventional Neurology Device market providing information such as company profiles, product picture, and specification, production, price, cost, revenue, and contact information. Details of different sections and sub-sections of the global market on the basis of topographical regions have been given. In terms of a global perspective, this report represents the overall market size by analyzing historical data and future prospects.

DOWNLOAD FREE SAMPLE REPORT: https://www.marketsandresearch.biz/sample-request/74333

NOTE: Our analysts monitoring the situation across the globe explains that the market will generate remunerative prospects for producers post COVID-19 crisis. The report aims to provide an additional illustration of the latest scenario, economic slowdown, and COVID-19 impact on the overall industry.

Primitive vendors included in the market are: Medtronic, Medikit Co., Ltd., Penumbra, Inc., Johnson and Johnson, Microport Scientific Corporation, Terumo Corporation, W.L. Gore & Associates, Merit Medical Systems, Inc, Stryker

Market Scenario:

The report also highlights on its applications, types, deployments, components, developments of this market. It scrutinizes a number of potential growth factors, risks, restraints, challenges, market developments, opportunities. The development of the industry is assessed with information on the current status of the global Interventional Neurology Device industry in various regions. The report also covers the recent agreements including merger & acquisition, partnership or joint venture, and the latest developments of the manufacturers.

The product types covered in the report include: Embolization & coiling, Neurothrombectomy Devices, etc.

The application types covered in the report include: Treatment of Cerebral Aneurysms, Treatment of Cerebral Vasospasm, Vertebroplasty, etc.

ACCESS FULL REPORT: https://www.marketsandresearch.biz/report/74333/global-interventional-neurology-device-market-2020-by-manufacturers-type-and-application-forecast-to-2025

Regional Segmentation:

The global version of this report with a geographical classification such as: North America (United States, Canada and Mexico), Europe (Germany, France, United Kingdom, Russia and Italy), Asia-Pacific (China, Japan, Korea, India, Southeast Asia and Australia), South America (Brazil, Argentina), Middle East & Africa (Saudi Arabia, UAE, Egypt and South Africa). The authors of the report have studied the regions having growth potential to help companies plan their future investments. Key regions are assessed, with sales, revenue, market share, and growth rate of Interventional Neurology Device in these regions, from 2020 to 2025. This chapter also studies the regulatory reforms and norms that are expected to impact the global market.

Customization of the Report:

This report can be customized to meet the clients requirements. Please connect with our sales team (sales@marketsandresearch.biz), who will ensure that you get a report that suits your needs. You can also get in touch with our executives on +1-201-465-4211 to share your research requirements.

Contact UsMark StoneHead of Business DevelopmentPhone: +1-201-465-4211Email: sales@marketsandresearch.bizWeb: http://www.marketsandresearch.biz

View post:
Global Interventional Neurology Device Market 2020 | Demand and Scope with Outlook, Business Strategies, Challenges and Forecasts to 2025 -...

Corlieve Therapeutics SAS Closes Seed Financing to Develop Therapies for Severe Neurological Conditions – Yahoo Finance

Posted on November 2, 2020 by Danzig

PARIS, Nov. 2, 2020 /PRNewswire/ -- Corlieve Therapeutics today announced the closing of its seed financing led by Kurma Partners and IDinvest Partners, together with Pureos Bioventures. Corlieve is focused on developing novel therapeutics for severe neurological disorders.

Corlieve's lead program employs a novel AAV gene therapy approach for the treatment of refractory temporal lobe epilepsy (TLE), the most commonly diagnosed focal epilepsy in humans. The program is based on pioneering science from INSERM, CNRS, Aix Marseille University and the University of Bordeaux, and is being developed in collaboration with REGENXBIO Inc. (Maryland, US), a leading gene therapy company. In addition, Corlieve has licensed REGENXBIO's NAV AAV9 technology for the TLE program. Corlieve is led by Chief Executive Officer Richard Porter, Ph.D., who brings to the Company over 25 years of neuroscience leadership experience in the pharmaceutical and biotech industries, including most recently as Chief Operating Officer of Therachon Holding AG until its acquisition by Pfizer in July 2019.

"I am excited to build Corlieve on a strong scientific foundation and with valuable support from our partners and investors," said Dr. Porter. "Our novel approach allows us to bring potentially game-changing treatments to patients with neurological diseases."

Corlieve's board will consist of Vanessa Malier, Managing Partner at Kurma, Anja Harmeier, Partner at Pureos Bioventures and Olivier Danos, Ph.D., Chief Scientific Officer of REGENXBIO.

"The formation of Corlieve with REGENXBIO is another validation of our approach to build companies on the basis of leading French science combined with a strong technology partner. We at Kurma are thrilled to support this emerging science to tackle TLE," said Ms. Malier.

"Our mission at REGENXBIO is to develop and enable the use of our proprietary NAV Technology Platform to advance new gene therapies for diseases with significant unmet needs," said Dr. Danos. "We are pleased to collaborate with Corlieve in this application of our NAV AAV9 technology to potentially treat patients suffering from TLE, for which better treatment modalities are needed."

Story continues

About Corlieve TherapeuticsCorlieve Therapeutics is a biotechnology company focused on bringing novel therapeutic options to patients with severe neurological disorders. The lead project is targeting aberrantly expressed kainate receptors in the hippocampus of patients with TLE using a gene therapy approach.

About KurmaKurma Partners is a key European player in the financing of Innovation in Healthcare and Biotechnology, from pre-seed to growth capital, notably through Kurma Biofund I through III and Kurma Diagnostics, as well as via strategic partnerships with prestigious European research and medical institutions.

About IDinvestIdinvest Partners is a leading European mid-market private equity firm. With 8bn under management, the firm has developed several areas of expertise including innovative start-up venture capital transactions; mid-market private debt, i.e. single-tranche, senior and subordinated debt; primary and secondary investment and private equity advisory services.

About Pureos BioventuresPureos Bioventures is a newly formed venture capital fund, advised by Bellevue Asset Management. Pureos invests exclusively in private innovative drug development companies, with a special emphasis on the next generation of biological drugs and drug modalities. The fund's portfolio companies are built on scientific excellence to develop therapies across a broad indication spectrum including oncology, immunology, ophthalmology, rare diseases and neuroscience. Pureos has built a team with deep investment, operating and clinical expertise, that strives to impact patients' lives by advancing innovative treatments for devastating diseases.

About REGENXBIOREGENXBIO is a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. REGENXBIO's NAV Technology Platform, a proprietary adeno-associated virus (AAV) gene delivery platform, consists of exclusive rights to more than 100 novel AAV vectors, including AAV7, AAV8, AAV9 and AAVrh10. REGENXBIO and its third-party NAV Technology Platform Licensees are applying the NAV Technology Platform in the development of a broad pipeline of candidates in multiple therapeutic areas.

Contact: Amy Conrad, 858-366-3243, amy@juniper-point.com

View original content to download multimedia:http://www.prnewswire.com/news-releases/corlieve-therapeutics-sas-closes-seed-financing-to-develop-therapies-for-severe-neurological-conditions-301164506.html

SOURCE Corlieve Therapeutics

The rest is here:
Corlieve Therapeutics SAS Closes Seed Financing to Develop Therapies for Severe Neurological Conditions - Yahoo Finance

Health Matters: Neurology and the Keto Diet – NBC2 News

Posted on November 2, 2020 by Danzig

Its high in fat, moderate in protein, and low in carbohydratesthe ketogenic diet is known for helping patients lose weight. But sleep medicine Dr. Jose Colon says, if done correctly, the diet can improve more than just your weight. Being on a ketogenic diet or being in a state of ketosis, has been shown to help with epilepsy and many other disorders as well, Dr. Jose Colon, a sleep medicine physician with Lee Health.

Doctors use the ketogenic diet to help treat patients with seizures. The ketogenic diet is very effective in epilepsy but its also been shown to be helpful in many other medical disorders, from weight loss to diabetes, type two diabetes, insulin resistance, it can help with PCOS, and it helps brain function from pediatric to geriatric, from autism to Alzheimers, he said.

The keto diet can also benefit patients who suffer from sleep disorders. Ive had several patients also have successful treatment of narcolepsy as well with the ketogenic diet. One of the things with narcolepsy is that your brain is in a sleepy state and high carbohydrate states turn off your alerting neurons so it can help with that disorder as well, said Dr. Colon.

Doctors can help patients successfully adapt and maintain a ketogenic diet. A lifestyle change that can benefit their overall health.

View More Health Matters video segments at LeeHealth.org/Healthmatters/

Lee Health in Fort Myers, FL is the largest network of health care facilities in Southwest Florida and is highly respected for its expertise, innovation and quality of care. For more than 100 years, weve been providing our community with personalized preventative health services and primary care to highly specialized care services and robotic assisted surgeries. Lee Health Caring People. Inspiring Care.

Visit LeeHealth.org

Read more from the original source:
Health Matters: Neurology and the Keto Diet - NBC2 News

Neurologist at centre of NI’s biggest ever patient recall Dr Michael Watt will contest decision to appeal his voluntary removal from medical register…

Posted on December 8, 2021 by Danzig

A neurologist at the centre of Northern Ireland's biggest ever patient recall will contest a decision to appeal his voluntary removal from the medical register, the High Court heard today.

ounsel for Dr Michael Watt confirmed his intention to resist the surprise intervention by an oversight body.

Lawyers representing former patients welcomed the step taken by the Professional Standards Authority (PSA), but stressed they must not be shut out from the legal process.

In October the Medical Practitioners Tribunal Service (MPTS) granted Dr Watt's application for voluntary erasure from the register.

The regulator's controversial decision means the former Belfast Trust consultant will not face a public hearing into concerns about his work.

His inability to engage with a fitness to practice assessment and the potential risk of suicide were cited among the reasons.

Some of those Dr Watt treated are seeking a judicial review of the lawfulness of the decision.

Danielle O'Neill, 39, claims there was no jurisdiction for the move which breaches her human rights.

Belfast man Michael McHugh, 51, also alleges it was an unjust step, denying public scrutiny of the neurologist's work.

But it has now emerged that the PSA, which oversees regulators, has lodged a High Court appeal against the MPTS decision to allow voluntary removal.

A judge questioned whether the judicial review challenges should be put on hold pending the outcome of the separate legal action.

He was told that the neurologist intends to oppose the PSA's challenge.

David Dunlop QC confirmed: "It will come as no surprise that Dr Watt will be contesting the appeal, on the grounds that it seeks to challenge the basis on which the voluntary erasure application was approved."

During the hearing counsel representing Ms O'Neill, Dessie Hutton QC, reiterated claims that the MPTS decision was a nullity.

"If that argument is correct, there was never any basis for the decision, and there is no basis for the appeal," he submitted.

Adjourning proceedings, Mr Justice Colton stressed all of the cases should be reviewed again as soon as possible.

Outside court Ms O'Neill insisted that her legal action represents an opportunity for patients' to be heard.

She added: "I find it galling that Dr Watt, who should have a back seat in these proceedings, after all we have suffered, is now seeking to dictate how our cases will be heard."

Her solicitor claimed the voluntary removal decision had closed off the only remaining public hearing into alleged clinical failings which have caused "harm and immeasurable distress".

Claire McKeegan of Phoenix Law said: "Our clients (in the) Neurology Recall Support Group, who have been injured and traumatised, welcome the intervention of the Professional Standards Authority but wish to have a voice and participate in the court process." end

Link:
Neurologist at centre of NI's biggest ever patient recall Dr Michael Watt will contest decision to appeal his voluntary removal from medical register...

Katerina Akassoglou elected to National Academy of Inventors – EurekAlert

Posted on December 8, 2021 by Danzig

image:Katerina Akassoglou, senior investigator at Gladstone Institutes, is named a fellow of the National Academy of Inventors for her long track record of discovery and innovation. view more

Credit: Gladstone Institutes

Katerina Akassoglou, PhD, senior investigator at Gladstone Institutes, has been named a fellow of the National Academy of Inventors (NAI). Election to NAI is the highest professional distinction given solely to academic inventors.

This prestigious recognition is a testament to Akassoglous long track record of discovery and innovation. She has made seminal discoveries on the relationship between the brain, immune, and vascular systems. Her research has illuminated the toxic role of blood proteins in neurological diseases and has led to the development of therapeutics to treat these diseases.

Akassoglou holds 10 issued US patents and several pending patent applications, many of which have been licensed by biomedical companies. She co-founded the startup Therini Bio with technology spun out from her laboratory for the clinical development of these discoveries.

Katerina exemplifies Gladstones commitment to innovation, invention, and translational research that has the potential to benefit patients, says Gladstone President Deepak Srivastava, MD. We are incredibly proud that she has been recognized with this well-deserved honor.

Akassoglou was named an NAI Fellow for demonstrating a highly prolific spirit of innovation in creating or facilitating outstanding inventions that have made a tangible impact on the quality of life, economic development, and welfare of society.

I am truly honored to be elected to the National Academy of Inventors in recognition of our discoveries and grateful for the support of academic innovation, says Akassoglou, who is also director of the Center for Neurovascular Brain Immunology at Gladstone and UCSF, and professor of neurology at UC San Francisco. Election to the NAI further encourages us to pursue challenging problems in biology and medicine to develop urgently needed treatments for devastating human diseases.

Akassoglous research team discovered that blood proteins are toxic when they enter the brain in neurological diseases because they induce inflammation and inhibit repair. They showed that in neurodegenerative diseasesincluding multiple sclerosis and Alzheimers diseasethe blood-clotting protein fibrin leaks through the blood-brain barrier into the brain. There, it hijacks receptors on nervous system cells and can activate microglia (the brains resident immune cells), triggering inflammation and, eventually, nerve damage.

With this knowledge, Akassoglou invented an antibody to neutralize the toxic effects of blood in disease. This first-in-class immunotherapy targets fibrin and prevents it from activating immune cells, but doesnt impair its beneficial blood clotting function. In mouse models of Alzheimers disease, the antibody prevents neurodegeneration, even when administered after mice have already developed accumulations of amyloid proteins in the brain, a hallmark of disease. Similarly, in a mouse model of multiple sclerosis, the fibrin antibody prevented paralysis, nerve damage, and inflammation. Her lab also developed a fibrin therapeutics platform and, together with collaborators, discovered small molecule drugs to block the deleterious effects of fibrin on nervous system cells with potent protection from neurodegeneration.

Akassoglou is among 164distinguished academic inventors from 116universities and research institutes elected to the NAI this year. She becomes the second Gladstone researcher to be an NAI Fellow, with Senior Investigator Jennifer Doudna, PhD. An induction ceremony for newly elected NAI Fellows will be held at the organizations 11th annual meeting in June2022 in Phoenix, Arizona.

The program currently has 1,403Fellows worldwide representing more than 250 universities and research institutes. Collectively, fellows hold more than 42,700issued US patents, which the NAI estimates have generated more than $3trillion in revenue and created more than 1million jobs.

###

About the National Academy of Inventors

The National Academy of Inventors is a member organization comprising U.S. and international universities, and governmental and non-profit research institutes, with over 4,000 individual inventor members and Fellows spanning more than 250 institutions worldwide. It was founded in 2010 to recognize and encourage inventors with patents issued from the United States Patent and Trademark Office (USPTO), enhance the visibility of academic technology and innovation, encourage the disclosure of intellectual property, educate, and mentor innovative students, and translate the inventions of its members to benefit society. The NAI has a close partnership with the USPTO and is one of three honorific organizations, along with the National Medals and National Inventors Hall of Fame, working closely with the USPTO on many discovery and innovation support initiatives. The NAI publishes the multidisciplinary journal,Technology and Innovation.

About Gladstone Institutes

To ensure our work does the greatest good, Gladstone Institutes focuses on conditions with profound medical, economic, and social impactunsolved diseases. Gladstone is an independent, nonprofit life science research organization that uses visionary science and technology to overcome disease. It has an academic affiliation with the University of California, San Francisco.

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.

See original here:
Katerina Akassoglou elected to National Academy of Inventors - EurekAlert

Global Neurology Software Market Expected to Reach highest CAGR: Epic, Athenahealth, Nextgen, healthfusion, Allscripts etc. – The Think Curiouser

Posted on November 2, 2020 by Danzig

This versatile composition of research derivatives pertaining to diverse concurrent developments in the global Neurology Software market is poised to induce forward-looking perspectives favoring unfaltering growth stance.

A newly compiled research report presentation on global Neurology Software market is aimed to unfurl veritable details about growth prognosis that are effectively harnessed by prominent market drivers and growth influencers.

The report also sheds light on various growth deterrents and retardants to offer a decisive understanding on barrier analysis to optimally identify growth retardants that stun growth in global Neurology Software market. In further report highlights, readers are equipped with thorough understanding on barrier identification and threat evaluation

Vendor Profiling: Global Market_Keywor Market, 2019-25:

DROT Analysis Driver Assessment: This section of the report also clearly identifies the major growth enablement triggers and drivers that push the growth trajectory.

Understanding Growth Retardants: This report further entails crucial details on notable growth hindering aspects that significantly arrest smooth growth ride. Besides identifying major growth retardants, the report proceeds further with assessing catastrophic developments.

Understanding Opportunities: The report proceeds further with unraveling details on dominant as well as latent opportunities that ensure growth spurt through the growth span. This section of the report also includes veritable details on various M&A developments, commercial collaborations as well as segment wise advances that collectively direct optimistic growth.

We Have Recent Updates of Neurology Software Market in Sample [emailprotected] https://www.orbismarketreports.com/sample-request/121767?utm_source=PujaM

Favoring utmost reader comprehension about the Neurology Software market to ensure lucrative business returns, this mindful report is designed to include a dedicated chapter on pre and post COVID analysis to encourage steady recovery from the pandemic, affecting production and consumption facets critically.

Analysis by Type: This section of the report includes factual details pertaining to the most lucrative segment harnessing revenue maximization.

Analysis by Application: Further in the subsequent sections of the report, research analysts have rendered precise judgement regarding the various applications that the Neurology Software market mediates for superlative end-user benefits.

Browse Full Report with Facts and Figures of Neurology Software Market Report at @ https://www.orbismarketreports.com/global-neurology-software-market-analysis-by-growth-and-forecast-2025?utm_source=PujaM

Understanding Competition Spectrum: Global Neurology Software Market

In addition to the above, this dedicated research report representing the current and historical developments in the global Neurology Software market have been prioritized exponentially in report contents to ensure seamless growth oriented business discretion amongst frontline players

The report is as well designed to suit investment priorities of emerging market participants keen at sustaining indispensable market position amidst glaring odds and market challenges, inclusive of escalating competition.

This section of the report clearly demarcates the key market participants and contributors along with key manufacturers putting in dedicated efforts towards pandemic management.

Despite the temporary dip in growth prognosis owing the pandemic crisis, market participants in global Neurology Software market are scouting for accurate business strategies to emerge and offset critical growth deterrents in global Neurology Software market.

Brief on their company positioning, product and service status as well as likelihood of future investments as well as thorough objective analysis of the companies have been showcased in the report.

This highly classified information has been obtained post tremendous primary research practices undertaken by our inhouse research teams.

North America (U.S., Canada, Mexico) Europe (U.K., France, Germany, Spain, Italy, Central & Eastern Europe, CIS) Asia Pacific (China, Japan, South Korea, ASEAN, India, Rest of Asia Pacific) Latin America (Brazil, Rest of L.A.) Middle East and Africa (Turkey, GCC, Rest of Middle East)

Do You Have Any Query or Specific Requirement? Ask Our Industry [emailprotected] https://www.orbismarketreports.com/enquiry-before-buying/121767?utm_source=PujaM

The report offers a clear and accessible estimation of the global Neurology Software market that are presented as value based and volume based estimations. The report is mindfully structured to present all market relevant information which are designed and presented in the form of graphs, charts and tables to allow market players quickly decipher the peculiarities to invoke mindful business decisions

Global Neurology Software Market: Understanding Scope In-depth research and thorough evaluation of the various contributing factors reveal that the global Neurology Software market is estimated to perform decently in forthcoming years, reaching a total valuation of xx million USD in 2019, and is further poised to register xx million USD in 2025, growing at a healthy CAGR of xx%. This elaborate research report also houses extensive information of various market specific segments, elaborating further on segment categorization comprising type, application as well as end-user sections which successively influence lucrative business discretion.

The report also entails a dedicated section and chapter to offer market relevant highlights denoting consumption and production activities. The report also entails sectional representation of thorough barrier evaluation and threat probabilities. The report clearly highlights the details of vendor activities and promotional investments, crucial to ensure high return on investments.

About Us : We are a team of highly professional researchers dedicated to unravel ongoing market developments. We are recognized as best in industry one stop store, offering intensively researched market-oriented information with superlative standards of impartiality and authenticity in order to rightfully influence favorable business decisions across a range of verticals.

Contact Us : Hector CostelloSenior Manager Client Engagements4144N Central Expressway,Suite 600, Dallas,Texas 75204, U.S.A.Phone No.: USA: +1 (972)-362-8199 | IND: +91 895 659 5155

More:
Global Neurology Software Market Expected to Reach highest CAGR: Epic, Athenahealth, Nextgen, healthfusion, Allscripts etc. - The Think Curiouser

COVID-19 and Neuropsychiatric Symptoms in Teenagers : Neurology Today – LWW Journals

Posted on November 7, 2021 by Danzig

Article In Brief

Investigators reported anti-SARS-CoV-2 autoantibodies in the cerebrospinal fluid of three teens who came to the emergency department with neuropsychiatric symptoms. The scientists believe that emergency department doctors should be open to the possibility that young people presenting for the first time with unexplained neuropsychiatric problems could have an autoantibody response to the COVID-19 infection, and should be evaluated accordingly.

Scientists have identified anti-SARS-CoV-2 antibodies and anti-neuronal auto-antibodies in the cerebrospinal fluid (CSF) of two of three teenagers who presented to an emergency department with subacute neuropsychiatric problems, including paranoid delusions, suicidal ideation, anxiety, obsessive behavior, and cognitive slowing.

While many teenagers present to the emergency department with neuropsychiatric symptoms, these three teens were the only ones who presented to the University of California, San Francisco (UCSF) with these symptoms in the setting of a recent COVID-19 infection and for whom a neurology consult was called. Two tested positive with direct detection tests, and one was seropositive (antibody testing) with a recent exposure.

All three also had abnormal CSF with restricted oligoclonal bands, elevated protein, and/or an elevated immunoglobulin G (IgG) index. None of them met the criteria for multisystem inflammatory syndrome in children, which has been associated with some cases of COVID-19 in young patients.

The findings, published online on October 25 in JAMA Neurology, suggest that the virus could be associated with central nervous system inflammation and leave some pediatric COVID-19 patients with new onset neuropsychiatric symptoms that do not respond to traditional psychiatric medications.

One of the teenagers seemed to improve after immunotherapy, another had a modest response, while the third teens' symptoms improved after treatment with lorazepam and olanzapine without immunotherapy.

The scientists believe that emergency department doctors should be open to the possibility that young people presenting for the first time with unexplained neuropsychiatric problems could have an auto-antibody response to the COVID-19 infection, and should be evaluated accordingly.

We don't know if this could be a more general phenomenon, said the senior study author Michael R. Wilson, MD, FAAN, associate professor and Debbie and Andy Rachleff Distinguished Chair in neurology at the UCSF Weill Institute for Neurosciences. Scientists at UCSF are now analyzing CSF from more young people.

Together with Samuel J. Pleasure, MD, PhD, the Glenn W. Johnson, Jr. Memorial Endowed Chair in Neurology at UCSF, Dr. Wilson, and first co-author Christopher Bartley, MD, PhD, have been using multiple technologiesgenomics, immune system sequencing techniques, and phage displayto characterize the immune system's response to pathogens and to screen for antibodies in the CSF of COVID-19 patients with neurologic symptoms.

For this latest study, the scientists conducted a detailed analysis of CSF and blood from three teenagers presenting to UCSF Benioff Children's Hospital with neurological or psychiatric symptoms during a five-month period in 2020.

In the first case, UCSF pediatric resident Claire Johns, MD, had evaluated a teenager who presented with acute delusions and psychosis, and called on the neurology service to help assess the patient. The teenager had erratic and paranoid-like behavior, insomnia and social withdrawal. The teen had a history of marijuana use and unspecified anxiety and depression, was initially treated with psychiatric medications, but was discharged after 11 days. The teen was readmitted a day later with persistent delusions.

The teenager had tested positive for COVID-19 during the first hospitalization, although the teen had no respiratory symptoms. On readmission, a lumbar puncture showed elevated protein and elevated IgG index. An MRI of the brain showed non-specific T2/FLAIR white matter hyperintensities in the frontal lobes. The pediatric specialists ordered intravenous immunoglobulin (IVIg) and the teen quickly improved enough to be discharged from the hospital. The teen's blood and CSF were later sent for further analysis to Dr. Wilson and his colleagues who identified abnormal antibody production in the teen's CSF.

The second teen had a history of anxiety and motor tics and a foggy brain,: according to the description in the paper. The teen's father had just been diagnosed with COVID-19, and a week later the teen developed fever and respiratory symptoms and improved without treatment. Over the next six weeks, the teen experienced a host of neuropsychiatric symptoms, including word-finding difficulty and problems concentrating, insomnia, mood swings, and it morphed into aggression and suicidal ideation. The teen was treated without success with psychiatric medications, and admitted to the hospital ten weeks after the neuropsychiatric symptoms began.

Back in the hospital, the patient tested positive for SARS-CoV2 antibodies. The teen's slowed thinking and memory problems improved after IV methylprednisolone, and was discharged on lithium and risperidone. Six days later, still in the throes of aggression and suicidal ideation, the teen was readmitted. Another lumbar puncture showed elevated CSF protein and IVIg was administered for three days. The patient was discharged with psychiatric medicines but six months later there was still lingering forgetfulness and attention problems. A third lumbar puncture at six months still showed elevated protein.

The third teenager was taken to the emergency department after four days of extremely erratic and odd repetitive behaviors, insomnia, and anorexia. There was no previous history of psychiatric symptoms. In the ED, a SARS-CoV-2 test came back positive. The teen had an elevated white blood cell count, creatine kinase, and C-reactive protein as well as ideomotor apraxia, a lack of motivation, disorganized behavior, and agitation. Psychiatric medications were administered for a few days and then stopped. The patient's symptoms improved during the weeklong hospitalization, and the teen was discharged without any psychiatric medications.

One important difference is that the teen who improved was treated soon after their symptoms started whereas the second patient's treatment was delayed by over two months, said Dr. Johns. The third young person had mania and insomnia and tested positive for SARS-CoV2 but did not have evidence of auto-antibodies in the CSF.

You get to one underlying question: SARS-CoV-2 is infecting millions and millions of people, and a great majority don't get critically ill. The ones who do tend to be older and/or have co-morbidities. What we don't know is if there are underlying issues that put certain people at risk for neuropsychiatric problems or long COVID, said Dr. Pleasure.

Merely identifying these autoantibodies and some of their antigens does not causally link them to these young peoples' symptoms, added Dr. Bartley. In some patients, the specific regions of the SARS-CoV-2 proteome targeted by the serum antibodies differed from the antigens in the CSF, suggesting that a compartmentalized immune response might be occurring in the CNS.

But we won't build more confidence about a potential link until we've been able to assess additional patients to determine whether these autoantibodies consistently track with particular clinical phenotypes. Ultimately, these autoantibodies may be reflective of a broader immune dysregulation that is related to their symptoms, but it's too early to tell. These teenagers were treated as psychiatric patients and COVID was found incidentally. We should definitely have this on our radar. Some of these patients may have subtle evidence of neuroinflammation and warrant a different treatment approach.

The scientists published previous studies in 2020 that led up to this latest work. In a paper Cell Reports Medicine done in close collaboration with Shelli Farhadian, MD, PhD, and Serena Spudich, MD, at Yale University, they identified early evidence for CSF anti-neural autoantibodies using mouse brain tissue to look for immunofluorescence. They identified some of the antibody targets using a combination of immunoprecipitation-mass spectrometry with rodent brain lysates and phage display. Then, they validated their finding in tissue culture cells engineered to express these antigens. Ultimately, five of the seven adults had evidence for CSF autoantibodies.

The immune response was so jazzed up, said Dr. Pleasure. It is not at all clear yet whether these antibodies, some of which appear to be cross-reactive between SARS-CoV-2 and neural antigens, are responsible for any of the neuropsychiatric symptoms.

The UCSF team now has samples from more than 50 COVID-19 patients who have unexplained neuropsychiatric symptoms. UCSF scientists are also studying patients with long-haul COVID, and Dr. Bartley said that they want to run the same types of experiments to see if they can identify auto-antibodies that may correlate with their enduring symptoms.

This is an important study that links infectious SARS-CoV-2 with neurological and neuropsychiatric complications in young people, said Carlos A. Pardo, MD, professor of neurology and pathology at Johns Hopkins Medicine and division of neuroimmunology and neuroinfectious disorders. The finding of auto-antibodies in spinal fluid is fascinating. It implicates the immunological responses in the brain, or unmasks the immunological responses against the brain.

We need to better characterize the mechanism of how the antibody triggers acute and long-term neuropsychiatric problems, added Dr. Pardo, who also studies CSF in patients with difficult neurological complications, including COVID-19. His laboratory recently published a study in The Journal of Neurological Sciences showing that almost 77 percent of patients with COVID-19 neurological complications had anti-SARS-CoV2 antibodies in their CSF.

The new study in JAMA Neurology opens the door to see how COVID triggers neurological and neuropsychiatric symptoms, he added. We are still a bit far away from recommending immune-based treatments.

There is currently great interest among neurologists regarding the potential for COVID infections to stir up an autoinflammatory process and induce autoimmunity resulting in a targeted immune attack against proteins in the brain, said Sean J. Pittock, MD, director of Mayo Clinic's center for multiple sclerosis and autoimmune neurology and of Mayo's neuroimmunology laboratory. Patients with COVID infections may develop encephalopathies but the immunopathological mechanisms underlying these remain unclear.

In this study, the UCSF scientists used their human phage display immunoprecipitation sequencing (testing for antibodies targeting the entire human proteome) and identified a multitude of autoantigens. The heterogenous autoantigen signature identified between patients indicates complexity and makes conclusions difficult, Dr. Pittock said. The identification of two potential novel targets in Case 1 is of interest but again the clinical implications remain unclear.

Many patients without autoimmune disease harbor autoantibodies (organ and non-organ specific).The two protein targets reported in this paper are intracellular proteins, thus it is unlikely that antibodies targeting such proteins are pathogenic, he added. Antibodies targeting intracellular proteins can indicate a pathogenic T cell response, however, if this were the case one would expect a more persistent and less responsive disorder than transient, as in these patients.

Overall, these findings are interesting and raise lots of questions which should stimulate more research in this area, Dr. Pittock said. Future studies investigating larger numbers of patients with COVID-associated encephalopathies will hopefully define the antibody, chemokine and cytokine signatures of this and other viral encephalopathies. This will further our understanding of these conditions and potentially identify therapeutic targets allowing repurposing of biologics for therapy.

He also said that although not applicable in this study, we must be careful in drawing too many conclusions: young patients develop primary psychiatric illness frequently, and when this diagnosis is combined with high levels of concomitant infection, there may or may not be a causal relationship.

The findings are pointing us in an intriguing direction, added Sarosh Irani, MD, associate professor at University of Oxford and head of the Oxford Autoimmune Neurology Group. These young people had atypical forms of encephalitis. The patients were identified retrospectively and it's not known if their neuropsychiatric symptoms would have occurred anyway or were due to COVID. Nevertheless, this is a very interesting preliminary finding and now needs validation in a larger consecutive cohort, ideally the pre-and post-COVID era.

Local and remote interactions between macrophages and microglia in neurological conditions – DocWire News

Posted on December 8, 2021 by Danzig

This article was originally published here

Curr Opin Immunol. 2021 Dec 1;74:118-124. doi: 10.1016/j.coi.2021.11.006. Online ahead of print.

ABSTRACT

In the central nervous system (CNS) parenchymal macrophages are called microglial cells and have a distinct developmental origin and can self-renew. However, during pathological conditions, when the blood-brain-barrier becomes leaky, including after injury, in multiple sclerosis or with glioblastoma, monocyte-derived macrophages (MDM) infiltrate the CNS and cohabit with microglia. In neurodegenerative diseases such as Alzheimers disease or ALS, MDM mostly do not enter the CNS, and instead microglia take several identities. In the specific case of ALS, the affected motor neurons are even surrounded locally by microglia, while along the peripheral nerves, by MDM-derived macrophages. The specific functions and interactions of these different myeloid cells are only starting to be recognized, but hold high promise for more targeted therapies.

PMID:34864338 | DOI:10.1016/j.coi.2021.11.006

Read the original post:
Local and remote interactions between macrophages and microglia in neurological conditions - DocWire News

Type of Alzheimer’s With Intact Memory Offers New Research Paths – Medscape

Posted on January 20, 2021 by Danzig

Patients with a rare type of Alzheimer's disease do not show the memory loss characteristic of the condition even over the long term, new research suggests. They also show some differences in neuropathology to typical Alzheimer's patients, raising hopes of discovering novel mechanisms that might protect against memory loss in typical forms of the disease.

Dr Marsel Mesulam

"We are discovering that Alzheimer's disease has more than one form. While the typical Alzheimer's patient will have impaired memory, patients with primary progressive aphasia linked to Alzheimer's disease are quite different. They have problems with language they know what they want to say but can't find the words but their memory is intact," lead author Marsel Mesulam, MD, told Medscape Medical News.

"We have found that these patients still show the same levels of neurofibrillary tangles which destroy neurons in the memory part of the brain as typical Alzheimer's patients, but in patients with primary progressive aphasia Alzheimer's the nondominant side of this part of the brain showed less atrophy," added Mesulam, who is director of the Mesulam Center for Cognitive Neurology and Alzheimer's Disease at Northwestern University Feinberg School of Medicine, Chicago, Illinois. "It appears that these patients are more resilient to the effects of the neurofibrillary tangles."

The researchers also found that two biomarkers that are established risk factors in typical Alzheimer's disease do not appear to be risk factors for the primary progressive aphasia (PPA) form of the condition.

"These observations suggest that there are mechanisms that may protect the brain from Alzheimer's-type damage. Studying these patients with this primary progressive aphasia form of Alzheimer's may give us clues as to where to look for these mechanisms that may lead to new treatments for the memory loss associated with typical Alzheimer's disease," Mesulam commented.

The study was published online in the January 13 issue of Neurology.

PPA is diagnosed when language impairment emerges on a background of preserved memory and behavior, with about 40% of cases representing atypical manifestations of Alzheimer's disease, the researchers explain.

"While we knew that the memories of people with primary progressive aphasia were not affected at first, we did not know if they maintained their memory functioning over years," Mesulam noted.

The current study aimed to investigate whether the memory preservation in PPA linked to Alzheimer's is a consistent core feature or a transient finding confined to initial presentation, and to explore the underlying pathology of the condition.

The researchers searched their database to identify patients with PPA with autopsy or biomarker evidence of Alzheimer's, who also had at least two consecutive visits during which language and memory assessment had been obtained with the same tests.

The study included 17 patients with the PPA-type Alzheimer's disease. They were compared with 14 patients who had typical Alzheimer's disease with memory loss.

The authors point out that characterization of memory in patients with PPA is challenging because most tests use word lists, and thus patients may fail the test because of their language impairments. To address this issue, they included patients with PPA who had had memory tests involving recalling pictures of common objects.

Patients with typical Alzheimer's disease underwent similar tests but used a list of common words.

A second round of tests was conducted in the primary progressive aphasia group an average of 2.4 years later and in the typical Alzheimer's group an average of 1.7 years later.

Brain scans were also available for the patients with PPA, as well as postmortem evaluations for eight of the PPA cases and all the typical Alzheimer's cases.

Results showed that patients with PPA had no decline in their memory skills when they took the tests a second time. At that point, they had been showing symptoms of the disorder for an average of 6 years. In contrast, their language skills declined significantly during the same period. For typical Alzheimer's patients, verbal memory and language skills declined with equal severity during the study.

Postmortem results showed that the two groups had comparable degrees of Alzheimer's pathology in the medial temporal lobe the main area of the brain affected in dementia.

However, MRI scans showed that patients with PPA had an asymmetrical atrophy of the dominant (left) hemisphere with sparing of the right sided medial temporal lobe, indicating a lack of neurodegeneration in the nondominant hemisphere, despite the presence of Alzheimer's pathology.

It was also found that the patients with PPA had significantly lower prevalence of two factors strongly linked to Alzheimer's TDP-43 pathology and APOE 4 positivity than the typical Alzheimer's patients.

The authors conclude that: "Primary progressive aphasia Alzheimer's syndrome offers unique opportunities for exploring the biological foundations of these phenomena that interactively modulate the impact of Alzheimer's neuropathology on cognitive function."

In an accompanying editorial, Seyed Ahmad Sajjadi, MD, University of California, Irvine; Sharon Ash, PhD, University of Pennsylvania, Philadelphia; and Stefano Cappa, MD, University School for Advanced Studies, Pavia, Italy, say these findings have important implications, "as ultimately, preservation of cognition is the holy grail of research in this area."

They point out that the current observations imply "an uncoupling of neurodegeneration and pathology" in patients with PPA-type Alzheimer's, adding that "it seems reasonable to conclude that neurodegeneration, and not mere presence of pathology, is what correlates with clinical presentation in these patients."

The editorialists note that the study has some limitations: the sample size is relatively small; not all patients with PPA-type Alzheimer's underwent autopsy; MRI was only available for the aphasia group; and the two groups had different memory tests for comparison of their recognition memory.

But they conclude that this study "provides important insights about the potential reasons for differential vulnerability of the neural substrate of memory in those with different clinical presentations of Alzheimers pathology."

The study was supported by the National Institute on Deafness and Communication Disorders, the National Institute of Neurological Disorders and Stroke, the National Institute on Aging, the Davee Foundation, and the Jeanine Jones Fund.

Neurol. Published online January 13, 2021. Abstract, Editorial

For more Medscape Neurology news, join us on Facebook and Twitter

See more here:
Type of Alzheimer's With Intact Memory Offers New Research Paths - Medscape

Deep Brain Stimulation: The Answer to Chronic Pain? – Neurology Advisor

Posted on January 20, 2021 by Danzig

Chronic pain affects 1 in every 4 adults in the United States, many of whom are resistant to pharmacotherapy.1 It is a significant burden to both individuals and healthcare systems, affecting mental health, cognitive function, and promoting opioid dependency.2 However, researchers are hot on the heels of discovering new ways to treat the condition including via deep brain stimulation (DBS).

What is DBS?

DBS has the potential to treat a variety of neurological diseases by the implantation of electrical leads into specific areas of the brains cortex or subcortex, linking the leads to an implanted electrical stimulator.3 The appropriate areas of the brain are then stimulated with electrical current to ease or eliminate certain symptoms. While this treatment strategy is approved for motor diseases like essential tremors, dystonia, and Parkinsons disease, it is gaining increasing interest for pain relief in therapy-resistant individuals.4

DBS for the treatment of chronic pain

Since the 1950s, researchers have investigated DBS for the treatment of individuals with incurable, pain-inducing disorders.5 These investigations involved a variety of intractable pain syndromes, ranging from brachial plexopathy, injury of the spinal cord, and thalamic pain syndrome, to accident-related pain and mechanical lower back pain.6 Success has also been reported for incurable facial pain, although subsequent studies targeting different chronic pain disorders demonstrated inconsistent efficacy.5,6 Consequently, DBS is still considered investigational and off-label for chronic pain treatment today.

This off-label status has not hindered research, however. One study reported the results of 59 patients with a diverse range of chronic pain syndromes, who received DBS in the periventricular grey (PVG) area of the brain and/or the thalamus.7 In comparison to pre-operative levels, results indicated a drastic improvement, with more than half of patients, regardless of pain etiology, reporting pain relief by 50 percent.

Another study involved performing DBS on the periaqueductal grey (PAG) or PVG area, along with the sensory region of the thalamus or internal capsule, on patients with a variety of pain etiologies. Pain reduction exceeded 50 percent.8

Interestingly, some patients who fail to meet the 50 percent pain reduction criteria so often used in research testify to being greatly satisfied with any amount of pain reduction as it significantly improves their quality of life.9 This means that many patients are documented to have failed DBS treatment regardless of a partial, but notable, improvement.

Identifying novel target sites for chronic pain therapy

According to Prasad Shirvalkar, pain physician and Assistant Professor at the University of California, Historically, DBS has overwhelmingly targeted two brain regions: the ventral thalamus and the PAG areas. Thalamic DBS was hypothesized to work consistent with the Gate Control Theory of pain. It is believed that stimulating the thalamus produces tingling or other paraesthesia that effectively block pain-related transmission from fibers that provide input from the periphery and spinal cord. The Gate Control Theory posits that ascending fibers/inputs to the brain have limited bandwidth, and that providing some additional input may interfere with pain signal transmission. The PAG DBS may help by boosting the bodys endogenous opioid system, but there is some controversy over this.3

According to research, a low frequency below 50 Hz is presumed to have an analgesic effect upon thalamus and PAG stimulation, while higher frequencies above 70 Hz are presumed to increase pain sensitivity. Additionally, stimulation of the ventral posterolateral (VPL) and ventral posteromedial (VPM) nuclei causes a pleasant sensation that overrides pain, while stimulation of PVG and PAG areas triggers analgesia and a warm sensation over the painful region.9

More recently, a team at Oxford has introduced DBS of the anterior cingulate cortex (ACC), which may dampen the unpleasantness or bothersomeness of pain without affecting the somatosensory component of pain, says Shirvalkar. Patients have reported that even though pain was not totally relieved, it was less irritating or felt distant from them, demonstrating the emotional or affective aspect of the ACC.9

Overcoming barriers to the effective use of DBS

DBS currently involves a constant flow of electrical current and does not adjust to changes in brain activity.1 According to Shirvalkar, One of the biggest obstacles with DBS for pain is that no matter which target is stimulated, DBS often loses effect in the long term over 1-2 years for many patients. That is, the brain seems to adapt to the stimulation and ignores it. We are trying to figure out how to overcome such adaptation.3

It is more likely that multiple brain regions conspire over a network to produce and perpetuate chronic pain states, Shirvalkar explains. We are conducting a clinical trial that incorporates a novel trial period, where patients temporarily have electrodes placed in their brain for a period of 10 days. We then work very hard over 10 days to record brain activity and stimulate multiple regions that we believe are important for chronic pain. This way, we can determine which sites or nodes are most pain-relieving when stimulated for that individual person. By performing a comprehensive trial period, Shirvalkar and his team can learn more about the network behavior of chronic pain in the brain and maximize the probability of finding an efficacious therapy for each patient. Importantly, Shirvalkar says, This way, patients are not implanted with a permanent device when there is a low chance of long-term benefit.

Any emerging research findings could advance treatment for other conditions too. Other brain diseases that are treated with brain stimulation such as epilepsy, Parkinsons disease, and depression (although experimentally) could also benefit from developing technology where stimulation responds to ongoing neural activity, says Shirvalkar. Many of my colleagues are working on developing adaptive DBS for these other medical conditions.

The future of DBS for chronic pain

Going forward, Shirvalkar believes that there is the need for advancement in two key scientific areas. The first is understanding basic brain mechanisms that underlie these diseases so that we can better understand what effect stimulation is actually having on the disease itself, he says. The second is figuring out how we can modulate the key brain circuits non-invasively, using transcranial magnetic stimulation or scalp stimulation. I think the future is moving away from stimulating single brain regions and towards networks, ultimately with the goal of doing this without invasive implants.

References

1. Miller, JA. Tailoring deep brain stimulation to treat chronic pain. UC San Francisco. Published February 3, 2020. Accessed December 20, 2020. https://www.ucsf.edu/news/2020/02/416601/tailoring-deep-brain-stimulation-treat-chronic-pain.

2. Dydyk AM, Yarrarapu SNS, Conermann T. Chronic Pain. StatPearls; 2020. Updated November 8, 2020. https://www.ncbi.nlm.nih.gov/books/NBK553030/

3. Shirvalkar P, Sellers KK, Schmitgen A, et al. A Deep Brain Stimulation Trial Period for Treating Chronic Pain. J Clin Med. 2020;9(10):3155. doi:10.3390/jcm9103155

4. Lozano AM, Lipsman N, Bergman H, et al. Deep brain stimulation: current challenges and future directions. Nat Rev Neurol. 2019;15(3):148-160. doi:10.1038/s41582-018-0128-2

5. Frizon LA, Yamamoto EA, Nagel SJ, Simonson MT, Hogue O, Machado AG. Deep Brain Stimulation for Pain in the Modern Era: A Systematic Review. Neurosurgery. 2020;86(2):191-202. doi:10.1093/neuros/nyy552

6. Ben-Haim S, Mirzadeh Z, Rosenberg WS. Deep brain stimulation for intractable neuropathic facial pain. Neurosurg Focus. 2018;45(2): E15. doi:10.3171/2018.5.FOCUS18160

7. Boccard SGJ, Pereira EAC, Moir L, Aziz TZ, Green AL Long-term outcomes of deep brain stimulation for neuropathic pain. Neurosurgery. 2013; 72:221-230. doi:10.1227/NEU.0b013e31827b97d6

8. Kumar K, Toth C, Nath RK Deep brain stimulation for intractable pain: A 15-year experience. Neurosurgery. 1997; 40:736-746. doi:10.1097/00006123-199704000-00015

9. Farrell SM, Green A, Aziz T. The Current State of Deep Brain Stimulation for Chronic Pain and Its Context in Other Forms of Neuromodulation. Brain Sci. 2018;8(8):158. doi:10.3390/brainsci8080158

More here:
Deep Brain Stimulation: The Answer to Chronic Pain? - Neurology Advisor

Sosei Heptares to Explore Structure-based Drug Discovery (SBDD) Approaches to Ion Channels through Strategic Technology Collaboration with Metrion…

Posted on February 2, 2021 by Danzig

TOKYO and CAMBRIDGE, England, Feb. 1, 2021 /PRNewswire/ -- Sosei Group Corporation ("the Company"; TSE: 4565) announces it will apply its world-leading structure-based drug design (SBDD) expertise and platform to ion channels for the first time through a new strategic collaboration with Metrion Biosciences Limited ("Metrion"), the specialist ion channel CRO and drug discovery company.

Ion channels are a class of integral membrane proteins that regulate the flow of ions across the cell membrane as a means of conducting signals between cells and their environment. They are well established drug targets, particularly in neurological and cardiovascular diseases, but many remain undrugged or poorly drugged, and may be tractable to structure-based approaches.

The collaboration aims to demonstrate the potential of Sosei Heptares' SBDD technologies to address disease-associated ion channels and work towards establishing a leadership position in this area, in a similar way that it has done for G protein-coupled receptors (GPCRs).

As a first step, Sosei Heptares and Metrion will combine their respective capabilities in a drug discovery program to identify novel, highly specific drug leads for further development against a single ion channel associated with neurological diseases.

Metrion will contribute intellectual property, know-how and use of screening models for the nominated ion channel target. Sosei Heptares will apply its technologies for structure determination studies and SBDD. Sosei Heptares will have exclusive, full global rights to all molecules identified and directed to the targets for development by Sosei Heptares. No further financial details are disclosed.

Rob Cooke, Chief Technology Officer of Sosei Heptares, commented: "We are extremely pleased to enter this collaboration with Metrion in the hugely exciting area of ion channels. Their experience enables us to extend our world-leading expertise in Structure-Based Drug Discovery for GPCRs to other membrane proteins where structural input to drug discovery has been more limited. This strategic technology collaboration is the latest in a series we have made with highly innovative companies in recent months designed to strengthen our platform and enhance our discovery and partnering opportunities. In addition to Metrion, these collaborations with Captor Therapeutics in targeted protein degradation and with PharmEnable to access proprietary artificial intelligence-enabled and medicinal chemistry technologies are a key factor to drive our future growth ambitions."

Andrew Southan, Chief Executive Officer of Metrion Biosciences, added: "Resolving the 3D structure of ion channel proteins has great potential to accelerate the discovery of potent, selective new drugs targeting this highly important class of human proteins. This opportunity to combine Metrion Biosciences' depth of target class knowledge and assay expertise with Sosei Heptares' Structure-Based Drug Discovery capabilities has considerable potential to achieve scientific and commercial breakthroughs in this field. On behalf of the entire Metrion team I would like to thank Sosei Heptares for selecting Metrion Biosciences for this work and we look forward to a successful alliance."

About Sosei Heptares

We are an international biopharmaceutical group focused on the discovery and early development of new medicines originating from our proprietary GPCR-targeted StaR technology and structure-based drug design platform capabilities. We are advancing a broad and deep pipeline of novel medicines across multiple therapeutic areas, including neurology, immunology, gastroenterology and inflammatory diseases.

We have established partnerships with some of the world's leading pharmaceutical companies, including AbbVie, AstraZeneca, Biohaven, Genentech (Roche), GSK, Novartis, Pfizer and Takeda and additionally with multiple emerging technology companies. Sosei Heptares is headquartered in Tokyo, Japan with corporate and R&D facilities in Cambridge, UK.

"Sosei Heptares" is the corporate brand and trademark of Sosei Group Corporation, which is listed on the Tokyo Stock Exchange (ticker: 4565). Sosei, Heptares, the logo and StaR are trademarks of Sosei Group companies.

For more information, please visit https://www.soseiheptares.com/

LinkedIn: @soseiheptaresco | Twitter: @soseiheptaresco | YouTube: @soseiheptaresco

About Metrion Biosciences

Metrion Biosciences is a specialist ion-channel contract research organization and drug discovery business. The Company provides customers with access to a range of high-quality ion channel assays on a fee-for-service or collaboration basis. Metrion Biosciences' ion channel expertise includes an industry leading panel of in vitro cardiac ion channel safety assays, translational native cell and phenotypic assays for neurological and cardiotoxicity testing, and a range of other ion channel screening services such as cell line development and optimization. Metrion Biosciences is able to provide tailored assay formats, data analysis and reporting solutions, effective project management and quality assured data packages.

For more information, please visit http://www.metrionbiosciences.com

LinkedIn: @metrion-biosciences | Twitter: @metrion_biosci

Enquiries:

Sosei Heptares Media and Investor RelationsHironoshin Nomura, SVP Investor Relations and Corporate Strategy+81 (0)3 6679 2178 | Hironoshin.Nomura@SoseiHeptares.com

Shinichiro Nishishita, VP Investor Relations, Head of Regulatory Disclosures+81 (0)3 5210 3399 | IR@SoseiHeptares.com

Citigate Dewe Rogerson (for Sosei Heptares)Yas Fukuda Japanese Media+81 (0)3 4360 9234 | Yas.Fukuda@citigatedewerogerson.com

Mark Swallow, David Dible International Media+44 (0)20 7638 9571 | SoseiHeptares@citigatedewerogerson.com

Metrion BiosciencesKatie Odgaard Zyme Communications+44 (0)7787 502 947 | katie.odgaard@zymecommunications.com

Forward-looking statements

This press release contains forward-looking statements, including statements about the discovery, development and commercialization of products. Various risks may cause Sosei Group Corporation's actual results to differ materially from those expressed or implied by the forward-looking statements, including: adverse results in clinical development programs; failure to obtain patent protection for inventions; commercial limitations imposed by patents owned or controlled by third parties; dependence upon strategic alliance partners to develop and commercialize products and services; difficulties or delays in obtaining regulatory approvals to market products and services resulting from development efforts; the requirement for substantial funding to conduct research and development and to expand commercialization activities; and product initiatives by competitors. As a result of these factors, prospective investors are cautioned not to rely on any forward-looking statements. We disclaim any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

View original content:http://www.prnewswire.com/news-releases/sosei-heptares-to-explore-structure-based-drug-discovery-sbdd-approaches-to-ion-channels-through-strategic-technology-collaboration-with-metrion-biosciences-301218515.html

SOURCE Sosei Heptares

Company Codes: Berlin:JSS, OTC-PINK:SOLTF, Tokyo:4565, Frankfurt:JSS, Munich:JSS, OtherOTC:SOLTF, Stuttgart:JSS

Read this article:
Sosei Heptares to Explore Structure-based Drug Discovery (SBDD) Approaches to Ion Channels through Strategic Technology Collaboration with Metrion...

Diabetes, Hypertension Linked to COVID-19-Related Neurological Complications – MD Magazine

Posted on November 30, 2020 by Danzig

This article was originally published on Diagnostic Imaging.

According to a new study, coronavirus disease 2019 (COVID-19) positive patients who had hypertension and type 2 diabetes were more likely to experience the neurological complications, including bleeding in the brain and stroke, that come with the virus.

Based on CT and MRI images, investigators from the Perelman School of Medicine at the University of Pennsylvania determined that these chronic conditions could play a role in which patients are impacted by more than just the hallmark lung inflammation that comes with viral infection.

COVID-19s effects extend far beyond the chest, said lead study author Colbey W. Freeman, M.D., chief resident in the Penn Medicine radiology department. While complications in the brain are rare, they are an increasingly reported and potentially devastating consequence of COVID-19 infection.

Freemans team will present their findings during this years Radiological Society of North America (RSNA) annual meeting.

In an effort to better understand how COVID-19 impacts the body, they examined head CT and/or MRI images for patients positive for the virus who presented to the University of Pennsylvania health system from January 2020-April 2020.

A total of 81 of the 1,357 COVID-19-positive patients who were admitted underwent a brain scan prompted by either altered mental state or focal neurological deficits, including speech and vision problems.

Based on the teams analysis, 18 patients slightly over 20% had findings that were considered critical, such as strokes, brain bleeds, or blocked blood vessels. And, of that group, at least half also had a pre-existing history of high blood pressure or type 2 diabetes.

COVID-19 is associated with neurological manifestations, and hypertension and type 2 diabetes mellitus are common in individuals who develop these manifestations, Freeman said. These populations may be at higher risk for neurologic complications and should be monitored closely.

The team also found that two-thirds of the patients who had critical findings were African American, indicating COVID-19 positive patients in that minority group should be monitored more closely. And, among the entire group of 18 with emergent findings, three died while in the hospital, the team said.

Although this study revealed a role for high blood pressure and type 2 diabetes in the neurological impact of the virus, investigators still do not know exactly what causes those complications.

The mechanisms could be multi-factorial, and the generally accepted belief is that infection-associated inflammation is responsible, they said. In this study, in particular, they reported blood markers for inflammation were high in patients who had critical results.

When your body is in an inflammatory state, it produces all these molecules called cytokines to help recruit the immune system to perform its function, Freeman said. Unfortunately, if cytokines are over-produced, the immune response actually starts doing damage.

Using data from this study, the team is also looking at the how frequently COVID-19-positive patients on extracorporeal membrane oxygenation (ECMO) a pump system that circulates and replenishes oxygen in the blood experience neurological complications. Many patients included in this study required ECMO during hospitalization.

Future plans include a larger prospective study to investigate delayed, long-term, and chronic neurologic manifestations that have not currently been identified, but that might manifest later.

The study, "Diabetes, Hypertension May Increase Risk of COVID-19 Brain Complications," was published online by RSNA.

Original post:
Diabetes, Hypertension Linked to COVID-19-Related Neurological Complications - MD Magazine

Tilray, Inc. and Hormosan Sign a Cooperation Agreement for the Promotion of Medical Cannabis Extracts in Germany – Business Wire

Posted on December 4, 2020 by Danzig

BERLIN & FRANKFURT, Germany--(BUSINESS WIRE)--Tilray, Inc. (Tilray or the Company) (Nasdaq: TLRY), a leading company in the manufacture, research and distribution of medical cannabis, announced that it has entered into a co-promotion agreement with Hormosan for its full-spectrum cannabis extracts in Germany effective 1 January 2021.

Hormosan is primarily focused on pain therapy and neurology and is part of the Lupin Group, an international entity that sells innovative drugs and generics. Hormosan will support Tilray in its marketing and sales activities of full spectrum cannabis extract in Germany. Through this strategic partnership, the expertise of both Tilray and Hormosan will be leveraged to expand Tilrays presence in the German market.

Tilray launched its full-spectrum cannabis extracts in October 2017 and last expanded the range in May 2020. The range includes an extract with a balanced THC-CBD ratio, a CBD-dominant extract with a low THC content and a pure THC full-spectrum extract. According to the legal regulation, the use of cannabis full-spectrum extracts is not restricted to a specific indication, but the treating doctor decides at their own discretion whether a treatment is suitable. The Tilray extracts are used for chronic pain, spasticity, sleep disorders and a variety of other indications.

"With Hormosan we have gained a partner that has excellent expertise and contacts in the field of pain therapy and neurology and will thus significantly increase the visibility of Tilray's full-spectrum cannabis extracts in the future," explains Sascha Mielcarek, Managing Director Europe at Tilray. This will give physicians and patients even better access to our medical cannabis extracts while supporting our goal of contributing to improved care for patients with medical cannabis."

As one of the leading providers of full-spectrum cannabis extracts, Tilray is an ideal partner for Hormosan. With the co-promotion of medical cannabis extracts, we are expanding our competence and our therapeutic range in the field of pain therapy and neurology, comments Anjan Selz, Managing Director of Hormosan. "It is precisely the complementarity of medical cannabis with existing therapies that opens up promising options for doctors and their patients."

About Tilray

Tilray is one of the world's leading companies in the research, manufacture and distribution of medicinal cannabis and cannabinoids. Tilray has a broad product portfolio and can draw on experience with over 25,000 treated patients in fifteen countries on five continents. Further information can also be found at tilray.de.

About Hormosan

Hormosan Pharma GmbH was founded in Germany over 50 years ago and has been part of the international Lupin Group since 2008. With innovative and generic drugs, Hormosan supports the best possible treatment in the areas of neurology, pain therapy, as well as sexual health and HIV. In doing so, it focuses primarily on the medical needs of patients that have not yet been met, increasing patient benefits and the availability of alternative therapy options. Further information can also be found information at http://www.hormosan.de.

See the rest here:
Tilray, Inc. and Hormosan Sign a Cooperation Agreement for the Promotion of Medical Cannabis Extracts in Germany - Business Wire

Rare Neurological Disease Treatment Market: Growing prevalence of rare neurological diseases across the globe to drive the market – BioSpace

Posted on November 20, 2020 by Danzig

Global Rare Neurological Disease Treatment Market Overview

Rare neurological diseases are vastly underdiagnosed and most of them go untreated. Additionally, until recently there has been no specific treatments for such disorders. However, the landscape of the market is changing slowly. It is expected that the global rare neurological disease treatment market will have a great potential in the coming years of the forecast period ranging from 2020 to 2030. Increasing awareness about these diseases, advancing healthcare and neurobiological technologies, and fast track approvals of new treatment methods are some of the key factors that will help in pushing up the growth of the global market.

Read Report Overview - https://www.transparencymarketresearch.com/rare-neurological-disease-treatment-market.html

Global Rare Neurological Disease Treatment Market Notable Developments

In terms of competitive landscape of the global neurological disease treatment market, there are several key players operating in the market space. This makes the competitive landscape a highly fragmented one. The companies in the market are mainly focusing on developing new and innovative therapeutics to diagnose and treat these neurological diseases. The market consists of a few significant players who dominate the market. Some of the leading market players include CSL Ltd, Kedrion Biopharma Inc., US WorldMeds LLC (Solstice Neurosciences LLC), Merz Pharma GmbH & Co. KGaA, Aquestive Therapeutics Inc., Bayer AG, Pfizer Inc., Novartis AG, Merck & Co. Inc. (EMD Serono Inc.), and Jazz Pharmaceuticals PLC.

Request Brochure of Report - https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=79898

Global Rare Neurological Disease Treatment Market Driver and Restraints

There are several factors that are responsible for the overall development of the global rare neurological disease treatment market. One of the key driving factor for the growth of the global market has been the increasing activities of research and development to find cures for such disorders. In recent years, there has been a growing prevalence of rare neurological diseases across the globe. Most of them go unnoticed or are underdiagnosed. A lack of effective treatment is the most prominent driving factor for the key players in the market that will help it grow in the coming years of the forecast period. Another important factor for the growth of the market is growth focus on fast-track approvals for new and upcoming therapies to treat such disorders. Furthermore, recent technological advancements in the field of neurology and neuro-biology has also fueled the development of the global neurological disease treatment market. Also, increasing awareness about early diagnosis of these disorders might help the market growth in coming years.

Request for Analysis of COVID-19 Impact on Rare Neurological Disease Treatment Market- https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=79898

One key restraining factor for the growth of the global neurological disease treatment market has been lack of standard treatment to cure these disorders.

Global Rare Neurological Disease Treatment Market Geographical Outlook

Based on the geographical segmentation, the global rare neurological disease treatment market is divided into five key regions. These regions are North America, Latin America, Europe, Asia Pacific, and the Middle East and Africa. Of these currently, the global neurological disease treatment market is expected to be dominated by the regional segment of North America. The region is expected to account for a larger chunk of the global market in coming years of the forecast period ranging from 2020 to 2030. One of the key reasons of the growth of the North America market has been the increasing prevalence of such rare neurological diseases across the region. According to the Center for Rare Neurological Disease Research report, rare neurological diseases have an impact on around 200,000 individuals in the US alone. In addition to this, growing healthcare spending and availability of a matured and well-established nature of healthcare infrastructure is expected to fuel the development of the North America region.

Pre Book Rare Neurological Disease Treatment Market Report - https://www.transparencymarketresearch.com/checkout.php?rep_id=79898&ltype=S

About Us

Transparency Market Research is a next-generation market intelligence provider, offering fact-based solutions to business leaders, consultants, and strategy professionals.

TMR believes that unison of solutions for clients-specific problems with right methodology of research is the key to help enterprises reach right decision.

Contact

Mr. Rohit BhiseyTransparency Market Research

State Tower,

90 State Street,

Suite 700,

Albany NY - 12207

United States

USA - Canada Toll Free: 866-552-3453

Email: sales@transparencymarketresearch.com

Website: https://www.transparencymarketresearch.com/

Continue reading here:
Rare Neurological Disease Treatment Market: Growing prevalence of rare neurological diseases across the globe to drive the market - BioSpace

Retrospective Analysis of Neurological Symptoms of Severe/Critical COVID-19 Patients in Sichuan Province – DocWire News

Posted on November 30, 2020 by Danzig

This article was originally published here

Sichuan Da Xue Xue Bao Yi Xue Ban. 2020 Nov;51(6):873-877. doi: 10.12182/20201160108.

ABSTRACT

OBJECTIVE: To retrospectively analyze the symptoms and characteristics of nervous system damage in severe/critically severe patients with coronavirus disease 2019 (COVID-19) in Sichuan province, with a view to providing basic references for the prevention and treatment of COVID-19.

METHODS: A total of 90 patients with severe/critically severe COVID-19 were included, who were diagnosed and treated in COVID-19 designated hospital of Sichuan province from 11 January 2020 to 20 March 2020. Clinical features, test results, treatment options and clinical outcomes were analyzed retrospectively.

RESULTS: Of 90 patients, there were 54 males and 36 females, with an average age of (53.9016.92) years. In addition to the classic symptoms such as fever and/or respiratory symptoms, 53 patients also had various degrees of neurologic manifestations, including 33 cases of fatigue, 21 muscle soreness, 12 dizziness, 8 headaches, 3 mental disorders, and 1 consciousness disorders and 1 case of neck pain. Compared with the patients without neurologic manifestations, those with neurologic manifestations took a longer time from admission to diagnosis of COVID-19 ( P<0.05), and received more antifungal treatment ( P<0.05).

CONCLUSIONS: Neurological symptoms are not uncommon in severe/critically severe patients with COVID-19, and its relatively difficult in the treatment. It should be paid attention in order to avoid misdiagnosis.

PMID:33236615 | DOI:10.12182/20201160108

See the rest here:
Retrospective Analysis of Neurological Symptoms of Severe/Critical COVID-19 Patients in Sichuan Province - DocWire News

Select Page ::